Pharmacological rescue of mutant CFTR protein improves the viscoelastic properties of CF mucus

Journal of Cystic Fibrosis

Volumn 15, Issue 3, 2016, Pages 295-301

  Gianotti, Ambra ^a   Capurro, Valeria ^a   Scudieri, Paolo ^a   Galietta, Luis J V ^a   Moran, Oscar ^b   Zegarra Moran, Olga ^a  

^a G GASLINI INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

CFTR; Ivacaftor; Lumacaftor; Micro rheology; Mucus; Multiple particle tracking

Indexed keywords

AMILORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; MUTANT PROTEIN;

AIRWAY; ARTICLE; BRONCHUS MUCOSA; CONFOCAL MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; LUNG FIBROSIS; RESPIRATORY EPITHELIUM; SUBMUCOSA; VISCOELASTICITY; BIOAVAILABILITY; CELL CULTURE TECHNIQUE; CYSTIC FIBROSIS; DRUG EFFECTS; GENETICS; METABOLISM; MICROFLUIDICS; MUCUS; PROCEDURES; RESPIRATORY MUCOSA; THEORETICAL MODEL;

AMILORIDE; AMINOPYRIDINES; BENZODIOXOLES; BIOLOGICAL AVAILABILITY; CELL CULTURE TECHNIQUES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL BLOCKERS; HUMANS; MICROFLUIDICS; MODELS, THEORETICAL; MUCUS; MUTANT PROTEINS; RESPIRATORY MUCOSA;

EID: 84960908845     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.11.003     Document Type: Article

References (30)

1. Riordan J.R. CFTR function and prospects for therapy. Annu Rev Biochem 2008, 77:701-726.
2. Gianotti A., Melani R., Caci E., Sondo E., Ravazzolo R., Galietta L.J., et al. Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis. Am J Respir Cell Mol Biol 2013, 49:445-452.
3. Pezzulo A.A., Tang X.X., Hoegger M.J., Alaiwa M.H., Ramachandran S., Moninger T.O., et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487:109-113.
4. Quinton P.M. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008, 372:415-417.
5. Voynow J.A., Rubin B.K. Mucins, mucus, and sputum. Chest 2009, 135:505-512.
6. King M. Mucus and its role in airway clearance and cytoprotection. Physiological basis of respiratory disease 2005, 409-416. BC Decker Inc, Hamilton, Ontario, Canada. Q. Hamid, J. Shannon, J. Martin (Eds.).
7. Verdugo P. Supramolecular dynamics of mucus. Cold Spring Harb Perspect Med 2012, 2. 10.1101/cshperspect.a009597.
8. Yang N., Garcia M.A., Quinton P.M. Normal mucus formation requires cAMP-dependent HCO3- secretion and Ca2+-mediated mucin exocytosis. J Physiol 2013, 591:4581-4593.
9. Gustafsson J.K., Ermund A., Ambort D., Johansson M.E., Nilsson H.E., Thorell K., et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 2012, 209:1263-1272.
10. Pedemonte N., Lukacs G.L., Du K., Caci E., Zegarra-Moran O., Galietta L.J., et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005, 115:2564-2571.
11. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Stack J.H., Straley K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011, 108:18843-18848.
12. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Dřevínek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
13. Okiyoneda T., Veit G., Dekkers J.F., Bagdany M., Soya N., Xu H., et al. Mechanism-based corrector combination restores δF508-CFTR folding and function. Nat Chem Biol 2013, 9:444-454.
14. Clancy J.P., Rowe S.M., Accurso F.J., Aitken M.L., Amin R.S., Ashlock M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012, 67:12-18.
15. Lai S.K., O'Hanlon D.E., Harrold S., Man S.T., Wang Y.Y., Cone R., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A 2007, 104:1482-1487.
16. Schuster B.S., Suk J.S., Woodworth G.F., Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013, 34:3439-3446.
17. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
18. Qian H., Sheetz M.P., Elson E.L. Single particle tracking. Analysis of diffusion and flow in two-dimensional systems. Biophys J 1991, 60:910-921.
19. Wirtz D. Particle-tracking microrheology of living cells: principles and applications. Annu Rev Biophys 2009, 38:301-326.
20. Galietta L.J.V., Lantero S., Gazzolo A., Sacco O., Romano L., Rossi G.A., et al. An improved method to obtain highly differentiated monolayers of human bronchial epithelial cells. In Vitro Cell Dev Biol Anim 1998, 34:478-481.
21. Kreindler J.L., Bertrand C.A., Lee R.J., Karasic T., Aujla S., Pilewski J.M., et al. Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009, 296:L257-L266.
22. Scudieri P., Caci E., Bruno S., Ferrera L., Schiavon M., Sondo E., et al. Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J Physiol 2012, 590:6141-6155.
23. Itani O.A., Chen J.H., Karp P.H., Ernst S., Keshavjee S., Parekh K., et al. Human cystic fibrosis airway epithelia have reduced Cl- conductance but not increased Na+ conductance. Proc Natl Acad Sci U S A 2011, 108:10260-10265.
24. Puchelle E., Jacquot J., Beck G., Zahm J.M., Galabert C. Rheological and transport properties of airway secretions in cystic fibrosis-relationships with the degree of infection and severity of the disease. Eur J Clin Invest 1985, 15:389-394.
25. Henke M.O., Renner A., Huber R.M., Seeds M.C., Rubin B.K. MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions. Am J Respir Cell Mol Biol 2004, 31:86-91.
26. Rubin B.K. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev 2007, 8:4-7.
27. Suh J., Dawson M., Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. Adv Drug Deliv Rev 2005, 57:63-78.
28. Cholon D.M., Quinney N.L., Fulcher M.L., Esther C.R.Jr, Das J., Dokholyan N.V., et al. Potentiator ivacaftor abrogates pharmacological correction of δF508 CFTR in cystic fibrosis. Sci Transl Med 2014, 6. [246ra96].
29. Veit G., Avramescu R.G., Perdomo D., Phuan P.W., Bagdany M., Apaja P.M., et al. Some gating potentiators, including VX-770, diminish δF508-CFTR functional expression. Sci Transl Med 2014, 6. [246ra97].
30. Flume P.A., Liou T.G., Borowitz D.S., Li H., Yen K., Ordoñez C.L., et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012, 142:718-724.